Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AC Immune S.A. (NQ: ACIU )

3.410 -0.100 (-2.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 423,233
Open 3.500
Bid (Size) 3.330 (8)
Ask (Size) 3.520 (1)
Prev. Close 3.510
Today's Range 3.320 - 3.510
52wk Range 1.900 - 5.140
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024
ACIU stock results show that AC Immune missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-27.29%
-27.29%
1 Month
+39.18%
+39.18%
3 Month
+13.29%
+13.29%
6 Month
+17.59%
+17.59%
1 Year
+74.87%
+74.87%

More News

Read More
Gold Down Over 1%; AC Immune Shares Spike Higher
Via Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Via Benzinga
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
Via InvestorPlace
Why Is Safe & Green Development (SGD) Stock Down 5% Today?
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Is AC Immune (ACIU) Stock Up 45% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
From AC Immune SA
Via GlobeNewswire
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
From AC Immune SA
Via GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
From AC Immune SA
Via GlobeNewswire
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
Via Benzinga
AC Immune Announces Pricing of Underwritten Offering of Common Shares
From AC Immune SA
Via GlobeNewswire
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
From AC Immune SA
Via GlobeNewswire
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
From AC Immune SA
Via GlobeNewswire
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
Via InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.